Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A trial in infants and toddlers in Burkina Faso showed that experimental malaria vaccine R21/MM confers 77% protection, an unprecedented level and the first malaria vaccine to exceed WHO’s goal of 75% efficacy. While a larger trial is needed to assess its safety and efficacy, R21/MM may substantially reduce child mortality in Sub-Saharan Africa. But this vaccine may be less relevant to Asia Pacific where malaria causes severe morbidity and mortality in all age groups, asymptomatic malaria infections are frequent, and the vaccine may not be effective against P. vivax.

Mosquito © CDC James Gathany

The groundwork for the miraculously rapid development of COVID-19 vaccines actually began a few decades ago with basic research on molecular subunit vaccine technologies. In April 2021, the same researchers from the University of Oxford who developed the Oxford/AstraZeneca vaccine announced extraordinary findings with their experimental malaria vaccine R21/MM, which also uses subunit technology.

While R21/MM may substantially reduce child mortality numbers in Sub-Saharan Africa, the new vaccine may have less direct relevance to the Asia Pacific’s malaria problem for several reasons highlighted in a post by Professor Kevin Baird.

The ideal vaccine for Asia Pacific would need to offer protection not just from illness, but infection, so the vaccinated could not be carriers at all. This ‘sterilising immunity’ is a tall order but scientists are in hot pursuit with another technology — live attenuated sporozoite vaccines — which may provide that protection. This kind of vaccination also proved effective across different species of parasites in laboratory animal models for malaria.

A malaria vaccine ideally suited to the Asia Pacific would offer sterilising immunity against infection by any of the five species of parasites in the region that naturally infect people. Health officials could target the many pockets and scattered zones of active malaria transmission in Asia for vaccination. Interrupting the cycle of malaria transmission for only a few months could eliminate it, making vaccination a brief intervention rather than a lifetime enterprise — as it is with almost all other vaccines.

Another type of vaccine — which prevents humans from infecting mosquitoes — is currently in development. These transmission-blocking vaccines would also help rid Asia of its malaria problem.

The full post is available on the East Asia Forum website

Similar stories

Improving access to care for people in Vietnam impacted by Hepatitis C: dissemination workshop to share findings of OUCRU’s community-based participatory research

OUCRU and HCMC Hospital for Tropical Diseases host a one-day research dissemination workshop for policy, healthcare, community, and research stakeholders. The workshop is the culmination of an OUCRU project: “Community-based participatory research to promote engagement with underserved communities at risk of Hepatitis C virus in Ho Chi Minh City, Vietnam”.

The journey of dreams, improving engagement with underserved populations at risk for Hepatitis C in Vietnam.

OUCRU Public and Community Engagement team produced a video based on their project “Community-based participatory research to promote engagement with underserved communities at risk of Hepatitis C virus in Ho Chi Minh City, Vietnam”. This video was made by community members of the community-based participatory research to the project. The video is in Vietnamese with English subtitles

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Multidisciplinary dengue forecasting project launches in Vietnam

DART (Dengue Advanced Readiness Tools), is a new project supported by Wellcome to use climate data to better predict and prepare for infectious diseases outbreaks.

OUCRU’s Photographer In Residence Featured In The Lancet’s Highlights 2022

Photographs have the power to inform and engage viewers. Earlier this year, The Lancet invited submissions for Highlights, the publication’s annual photography competition. Highlights 2022 featured 14 winning photographs telling stories from a wide variety of health-related topics that captured the world’s attention in 2022. One of the powerful images selected was from Pearl Gan, OUCRU’s Photographer in Residence.

Researchers call for antimicrobial resistance surveillance to be improved

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.